• Lexaria Bioscience Corp. featured in a Technical420 article praising the company’s recent developments
• Lexaria is improving and strengthening patent portfolio; 19 patent applications are pending in more than 40 countries
• Company executes partnership with NeutriSci International; joint venture allows LXRP to enter Asian market

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), an innovative company licensing proprietary technology for the delivery of bioactive compounds including cannabinoids, is a “plant-to-bloodstream” company expected to draw investors in the cannabis marketplace. Lexaria has patented and licenses a novel delivery system that infuses organically sourced hemp oil into the molecules of other substances.

Cannabidiol, noted for its anti-inflammatory, anxiolytic, antiemetic and antipsychotic effects, is just one of several compounds targeted by Lexaria for its unique oral ingestion technology, which allows more efficient delivery of bioactive substances via oral ingestion without the need for unhealthy inhalation or the addition of sweeteners commonly used to mask bitter tastes. Non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and vitamins are among the substances targeted by Lexaria’s new delivery method.

A recent article in Technical420 (http://dtn.fm/C5gjS), a provider of research and analysis of cannabis stocks, praised the company for several positive developments over the past few months.

Lexaria has 19 patent applications filed and pending in more than 40 countries worldwide. The company strengthened its intellectual property portfolio with its first U.S. patent, issued in October 2016. The patent protects Lexaria’s intellectual property for infusion of cannabinoid compounds in edible products. Lexaria’s unique process improves the taste and bioavailability of cannabinoid food ingredients.

Another strong development is Lexaria’s joint venture with NeutriSci International (TSX.V: NU), a Canadian public company, to produce and sell a line of healthy edible cannabinoid products. The two companies will produce a line of cannabinoid mouth-melt products using Lexaria’s technology and NeutriSci’s proprietary pterostilbene tablet. Pterostilbene is an antioxidant that’s chemically similar to Resveratrol – a natural compound found primarily in blueberries and Pterocarpus marsupium heartwood, according to the U.S. National Library of Medicine (http://dtn.fm/5BkqA).

The joint venture will operate as Ambarii Trade Corporations, and initial operations will be funded equally by Lexaria and NeutriSci. AMbarii’s plans include securing licensees in Canada, California and Colorado to produce mouth-melt products containing THC.

Lexaria is also venturing into the Asian market, as noted by the Technical420 article. Ambarii has entered into an LOI with Naturally Splendid Enterprises Ltd. (TSX.V: NSP) for production and distribution of the company’s sublingual full spectrum cannabidiol tablets in Japan and South Korea. With a population of 127 million, Japan is one of the world’s largest markets, and hemp oil containing cannabidiol is already legal in Japan. South Korea, with a population of 50 million, is expected to open its markets to hemp oil-sourced cannabidiol soon.

Lexaria will begin in vitro absorption studies to quantify improvements in absorption in human intestinal tissue and will conduct animal studies on whole-body reactions to the rapid and efficient delivery of cannabinoids, vitamins, NSAIDs and nicotine. Edible nicotine products could allow a healthier alternative to smoking, patches and nicotine gum. The article points out that the company’s R&D budget is fully funded from existing capital.

Lexaria has an improved cash position and an attractive valuation, the Technical420 article states, due to improved balance sheets and a much smaller warrant overhang. The company raised more than $1.7 million in April, and, from November 2016 through May 2017, the company raised more than $4 million in equity. Technical420 is “favorable” on these developments and expects to see significant advancement by Lexaria Bioscience.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Drug candidate for top cause of death in the United States
• Genetically-targeted therapy increases chances of recovery
• Interim efficacy analysis soon to be conducted by the Data Safety Monitoring Board

Atrial fibrillation affects up to six million people in the U.S. The condition, if untreated, can lead to blood clots, stroke, heart failure and other heart-related complications, but many medications currently in use to treat it come with worrying side effects, perhaps because of their one-size-fits-all approach. In an effort to mitigate the unwanted, unintended action of these agents, ARCA Biopharma, Inc. (NASDAQ: ABIO) is applying a precision medicine approach, developing genetically-targeted therapies for cardiovascular diseases, as it works to bring its lead candidate for atrial fibrillation, Gencaro™, to market. The company believes that by tailoring medical treatment to the individual genetic characteristics of patients, more effective therapies will be enabled, patient outcomes will be improved and health care costs will go down.

Atrial fibrillation (AFib) is the most common kind of heart arrhythmia, a condition where the heart beats too fast, too slow, or in an irregular fashion. In a heart suffering from AFib, the regular pumping action of its upper chambers, the atria, is impaired. As a result, blood flow to the lower chambers, the ventricles, is impeded. AFib increases a person’s risk for stroke by four to five times compared with people who do not have it, and strokes caused by complications from AFib tend to be more severe than strokes with other underlying causes. AFib causes 15%–20% of ischemic strokes, which occur when blood flow to the brain is blocked by a clot or by fatty deposits called plaque in the blood vessel lining.

According to the Centers for Disease Control and Prevention (http://dtn.fm/sCD06), “more than 750,000 hospitalizations occur each year because of AFib… (and) the condition contributes to an estimated 130,000 deaths each year. (In addition), the death rate from AFib as the primary or a contributing cause of death has been rising for more than two decades.” AFib costs the United States about $6 billion each year, and medical costs for people who have AFib are about $8,705 higher per year than for people who do not have AFib.

Current treatments for AFib include drugs for heart rate control, drugs for heart rhythm control, and blood thinners. These medication, however, give rise to a plethora of side effects, including breast enlargement, diarrhea, low blood pressure, and heart failure, as well as psychological problems. One class of drugs that controls heart rate is known as beta-blockers; drugs of this type work by reducing heart rate, an example of which is ARCA’s lead candidate, Gencaro.

Gencaro (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator, now under evaluation in a clinical trial for the treatment and prevention of recurrent AFib in heart failure patients with reduced left ventricular ejection fraction, or HFREF. The company believes that Gencaro’s mechanism of action (MOA) differs from other beta-blockers because of its sympatholytic (norepinephrine lowering) and inverse agonism (inactivation of constitutively active receptors) properties. Genetic variations in receptors in the cardiovascular system of the general population vary, and these variations are thought to be a factor in how well patients respond to treatment. With Gencaro, ARCA has developed a formulation which interacts positively with a genotype, beta-1 389 arginine homozygous, found in approximately 50 percent of the U.S. population. Consequently, a Gencaro regimen promises a reduced range of side effects for a larger population of patients.

In June 2017, ARCA announced database lock for the GENETIC-AF interim efficacy analysis to be conducted by the trial Data Safety Monitoring Board (DSMB). Locking or closing a database ensures that no unauthorized or unintentional changes are made after the final data entry, check-up, and analysis. GENETIC-AF is a phase 2B/3 double-blind, clinical superiority trial comparing the safety and efficacy of Gencaro to an approved drug, TOPROL-XL, for the treatment and prevention of recurrent AFib in heart failure patients with reduced left ventricular ejection fraction (HFrEF). The company expects to announce the DSMB’s recommendation based on this interim analysis in August 2017. The Gencaro development program was previously granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

For more information, please visit www.ARCABio.com

• Proxy to shareholders seeks a reduction in Net Element’s common shares from 400 million to 100 million
• NETE reaches 30-month term stock purchase agreement with Cobblestone Partners
• Sets August 10 meeting with NASDAQ to present plan for listing compliance

Net Element, Inc. (NASDAQ: NETE) has proposed to shareholders a reverse split of its common stock at a ratio of between 1-for-10 and 1-for-30 on the proxy at its annual meeting in 2017 (http://dtn.fm/mod3S). It also plans to put to a vote of shareholders a reduction in common stock from 400 million shares to 100 million shares in the hope that fewer shares will result in an increase in the market price of its common shares.

NETE is a cloud-based global financial company that accepts electronic payments in an omni-channel environment. It processes payments in what is becoming a cashless economy at point-of-sale and on mobile devices. It also offers clients management tools in its systems. A Zack’s Research Report (http://dtn.fm/1uNBd) projects that the company will generate revenues of $74.6 million by 2018.

In the SEC filing of the proxy (http://dtn.fm/lIbk9), NETE said that it will appeal the NASDAQ market’s deficiency letter in a meeting on August 10. NETE said the purpose of the reverse stock split amendment is to decrease the number of outstanding shares of common stock and potentially increase the market price of its common stock. A stay of the decision by NASDAQ is in effect pending an appeal by the company.

“The company is considering several paths to regain compliance with the minimum bid price requirement, including, among other things, a reverse stock split,” the company said in the filing.

The proxy also detailed its July 5, 2017, agreement with Cobblestone Partners, LLC, to purchase up to an aggregate of $10 million of NETE’s common stock over the 30-month term of the purchase agreement. Proceeds from the agreement will be used by the company for working capital and general corporate purposes. The proposal, approved by shareholders in the proxy, would permit Cobblestone Partners to buy in excess of 19.99% of NETE’s outstanding shares, as per NASDAQ rules.

In a letter to shareholders (http://dtn.fm/i2aLL), NETE management also said that it has a program of cost cuts that should be realized by the third quarter of 2017.

For more information, visit the company’s website at www.NetElement.com

• Fundamental value drivers of InMed Pharmaceuticals are its drug development pipeline and proprietary biosynthesis technology in cannabinoid manufacturing
• Biopharmaceutical company already has two drug candidates – INM-085 and INM-750 – in the multi-billion dollar ocular and dermatology markets
• INM-085 and INM-750 target markets valued in excess of $5 billion and $1 billion, respectively

InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://dtn.fm/UMfe5), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed. It may eventually lead to a product which encompasses cannabinoid compounds targeting pain-related receptors in the body.

InMed is a Vancouver-based preclinical stage biopharmaceutical company specializing in the development of cannabinoid-based therapies using novel drug therapies and delivery systems. Value drivers for the company are its proprietary process for cannabinoid manufacturing and its drug candidate pipeline. It already has two preclinical product candidates. INM-085 has been developed for the treatment of glaucoma, an eye disease that accounts for a greater than $5 billion global market. The other is INM-750 for the treatment of orphan disease epidermolysis bullosa (EB), which is characterized by fragile skin. There are no approved therapies for the disease in this $1 billion market.

The InMed Pharmaceuticals article in the Journal (http://dtn.fm/lxT2B) focuses on how THC impacts the peripheral cannabinoid (CB) receptors CB1 and CB2. The results are that THC activates the CB1 receptor to provide analgesic relief without side effects. The study results suggest that THC could provide a novel approach to offer that relief through the peripheral application of cannabinoids.

The article is titled, “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation.” The study was co-funded by Canadian non-profit organization Mitacs and InMed Pharmaceuticals. In a news release, Hossain, co-author of the findings report, said, “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.”

The result could be a valuable approach in the cannabinoid treatment of severe pain. The model used in this study mimics the muscle pain of temporomandibular joint disorders (TMD) that affect the jaw muscle. TMD is a chronic pain condition that’s difficult to treat.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

• New Chinese economy has produced new Chinese consumer
• Consumer has pent up demand
• Moxian provides platform to motivate and move consumers to retail outlets

There’s little doubt that economic forces have transformed the Chinese consumer markets. The meteoric rise of middle-class households, a new generation of tech savvy consumers and the powerful pull of e-commerce all promise immense new consumer opportunities in China. A long time in the making, China’s consumer class has arrived.

China’s state run economy has pushed and pulled the country from subsistence agrarians to leading edge high-tech manufacturing with workers and consumers evolving along the way. Over 40 years in the making and with huge pent up demand, the new Chinese consumer class is ready to fully engage the twenty-first century. Technologically astute, the new Chinese consumer is poised to dramatically impact the economy of not only China but also the world. Companies that operate in and cater to this new megalith of consumption stand to be handsomely rewarded.

Moxian, Inc. (NASDAQ: MOXC) caters to and focuses on the new Chinese consumer and, importantly, bridges e-commerce to brick-and-mortar retail. Moxian provides small- and medium-sized brick-and-mortar businesses with cutting-edge turnkey solutions to attract and maintain customers. Free to the consumer, Moxian’s creative and socially interactive online platforms and mobile applications are moving the burgeoning Chinese consumer from online views to retail purchases at Moxian’s brick-and-mortar retail client locations. Moxian’s seductive social network integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeps them engaged and encourages them to refer new customers.

The company’s ingenious online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both new and existing customers. These online interactions provide each business the data to analyze consumer likes, dislikes and trends. Moxian’s platforms provide businesses the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients drive retail traffic into the brick and mortar locations and give merchant clients the ability to study consumer behavior and custom-tailor offerings to consumers.

Moxian continues to expand its web platform in an effort to entice and draw in consumers to its business clients. The company just announced another strategic partnership with a major high end retailer (http://dtn.fm/NI6qO) that should provide synergies, new products and technologies and open new distribution channels in high-growth markets. “China’s retail industry is going through a major transformation where mobile payments, marketing tools and customer data analytics converge into one single platform, and Shewn is a good example of a nationwide merchant capitalizing on the power of such platform to improve its marketing efficiency,” James Tan, chief executive officer of Moxian, stated in the news release. “With the extension of our powerful Moxian+ mobile App platform to Shewn and its distribution network, we look forward to a mutually beneficial relationship between the two parties in years to come.”

Moxian is taking the initiative to capitalize on what is a generational opportunity, and it appears that the company is positioned to be amply rewarded.

For more information, visit the company’s website at www.Moxian.com

• NASDAQ Biotechnology Index up and climbing
• Developing new treatment for acute myeloid leukemia (AML)
• Lead candidate, Annamycin, now at phase II

Since a rising sea lifts all boats, it’s decidedly good news for Moleculin Biotech, Inc. (NASDAQ: MBRX) that the NASDAQ Biotechnology Index (NBI) is enjoying a spring tide. The index has offered a year-to-date return of over 17 percent and seems set to keep climbing. This benign environment gives Moleculin an opportunity to advance work on its leading anti-cancer drug candidates. The company has begun to identify and prepare testing sites in Europe and has already appointed a Lead European Principal Investigator.

Moleculin was featured on Business Insider (http://dtn.fm/8LbO7), in a piece that attributed the rise in the NBI to ‘recent FDA decisions and clinical trial developments’. Moleculin, a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, announced on August 3 that it had selected Bioscience SA (Bioscience), a Polish contract research organization (CRO) to begin identifying and preparing clinical testing sites in Poland for Annamycin. Annamycin is the company’s drug candidate for the treatment of relapsed or refractory acute myeloid leukemia (AML).

AML is a type of blood cancer that usually develops in cells destined to become leukocytes or immune cells. It stunts their development and, consequently, results in a profusion of immature cells. As these immature cells, also known as blast cells, continue to build up, they may find their way into the lymph nodes, the liver, the spleen, the testicles or the brain, with highly deleterious effect.

In 2016, about 21,380 people of all ages (11,960 men and boys and 9,420 women and girls) were diagnosed with AML in the United States, according to Cancer Net (http://dtn.fm/0pGqR). The condition is the second most common type of leukemia diagnosed in adults and children. It is rare for AML to occur before age 45, and the average age at the time of diagnosis is 67 years. However, roughly three-quarters of those who develop it die within five years.

Moleculin’s lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory AML. So far, there are promising indications that Annamycin can circumvent some of the problems encountered in current treatment regimens, such as the risk of cardiotoxity, where treatment drugs damage the heart, and multi-drug resistance. Moleculin also has two active pre-clinical small molecule candidates in the pipeline. The first is directed at modulating hard-to-target cell signaling mechanisms and appears capable of stimulating a patient’s natural immune system while also attacking tumors directly. The second candidate targets the metabolism of tumors and exploits a unique approach for crossing the blood brain barrier for the treatment of glioblastoma and other central nervous system malignancies.

Some of Moleculin’s anti-cancer drug candidates are based on license agreements with The University of Texas System on behalf of the MD Anderson Center. MD Anderson is one of the original three comprehensive cancer centers in the U.S., and, in 2016, was ‘ranked #1 for cancer care in the “Best Hospitals” report published by the U.S. News & World Report.’

For more information, please visit www.Moleculin.com

• Millions of Americans live in areas with little or no comprehensive health care
• MIHI establishing nationwide telemedicine network to provide specialty care
• Serving the underserved makes MIHI sole practitioner to millions

There’s no doubt that the U.S. health care system is fractured. Our patchwork quilt of health care services leaves many citizens isolated and medically stranded. Far beyond the current contentious health care debate, millions of Americans live in areas that have chronically suffered with little or no health care services. For various reasons of geography, economics or social circumstance, certain populations in the country have far too few primary care providers. Defined by the government as Medically Underserved Areas, recruiting physicians to these communities is challenging not only because of the population’s complex human needs and limited health care resources, but also due to a lack of available social amenities.

Decades ago, country doctors were common, but they are now scarce in the 21st century, creating a critical need for primary care physicians in rural areas. Small towns around the country face the loss of basic medical services, because they have so few doctors to run their clinics. Many attribute the dearth of rural doctors to the increasingly complex and specialized nature of medical practices and the rapid pace of technological advancement.

Within this void, Medical Innovation Holdings Inc. (OTC: MIHI) uses technology to target and serve these underserved. MIHI is addressing this pressing need by establishing a nationwide, multi-disciplinary specialist provider network to serve rural patients via a seamless, comprehensive and sophisticated telemedicine program. The company’s platform is designed to bring much needed access to quality health care in real time while generating substantial efficiencies and cost savings.

The company’s telemedicine platform offers a range of modalities of telemedicine to create a virtual multi-specialty practice bringing modern medicine to underserved communities. The company’s subsidiary, 3Point Care, provides personalized pairing of its specialty doctors with traditional primary doctors, connecting patients with specialty health care professionals.

With the ability to provide a vast array of health care-related services on its various technology platforms, the company intends to create a comprehensive health care-centric business ecosystem where multiple products and services can be offered. As the company expands its unique business model into a large national footprint, a vast network of underserved patients will receive much needed services and, in essence, make MIHI a sole practitioner and product provider to a large swath of the population.

For more information, visit the company’s website at www.MedicalInnovationHoldings.com

• Huge and exponentially growing global need
• Industry independent
• Established reputation for reliability and cost-effectiveness

If there’s one challenge that dominates almost every aspect of our modern information age, it is most certainly Big Data. Over and above the increasing number of ways Big Data can be processed and analyzed, depending upon the need, the most fundamental problem is the sheer storing of exponentially growing volumes of data produced by virtually every industry and institution.

With the skyrocketing number of technologies and applications available to individuals and organizations for capturing and digitizing visual, audio, text, numeric, and every other conceivable type of information, the jump in data storage requirements is staggering and continues to expand. There’s nowhere that demand for storage isn’t going through the roof.

High volume data storage has been the focal point of California-based Qualstar Corporation (NASDAQ: QBAK) for over two decades, centering on the design, development, and production of automated tape libraries for storing, retrieving, and managing all forms of critical electronic data, largely for network computing.

Serving markets through global resellers and distributors, the company’s solutions are compatible with virtually every operating system and platform and are “supported by applications packages from all leading developers.” Most importantly, by developing solutions targeting several vertical markets, Qualstar is able to address a wide range of sectors and opportunities, including:

• Media & Entertainment
• Oil & Gas
• Government & Military
• Education
• Information Technology
• Medical Imaging
• Banking
• Surveillance

For more information, please visit www.Qualstar.com

• IGC purchased exclusive rights to USF patent focused on preventing amyloid-beta plaques from aggregating on neurons
• Company plans to pursue clinical trials related to this patent on path to FDA approval
• In 2017, direct costs associated with Alzheimer’s and other dementias will total an estimated $259 billion, according to the Alzheimer’s Association
  

If you are an investor, there have been significant developments over the past year that you should be tracking. These include remarkable, if preliminary, results regarding the effect of THC on amyloid-beta plaques, the plaques on neurons associated with Alzheimer’s disease, as well as a critical link between the related technology and India Globalization Capital (NYSE MKT: IGC). This information was summarized in an article first published on Benzinga (http://dtn.fm/MS9cb) and recently adapted for HIGH TIMES (http://dtn.fm/w5DS9), titled “Marijuana Could Help Treat Alzheimer’s: Here’s How It Would Work”.

Details from these articles include:

• A paper published by the Salk Institute has validated a study by the University of South Florida, indicating that low doses of THC (one of the main chemical compounds present in marijuana) break up amyloid-beta plaques on neurons.
• The prestigious journal Nature then published a paper showing that “cognitive function was restored in old mice who were given low doses of THC.”
• After discovering that THC in low doses binds to amyloid-beta plaques, preventing them from aggregating on neurons, the University of South Florida filed a patent for that mechanism.
• Following intensive negotiations, India Globalization Capital, a diverse Maryland-headquartered company now focused on the development of cannabis-based therapies, bought the exclusive rights to that U.S. patent filing.

In the articles, Ram Mukunda, IGC CEO, states, “In Alzheimer’s Disease, beta-amyloid aggregates into a plaque-like substance that builds around the neurons and disrupts communication between them. So of course, if low-doses of THC can break up those plaques and prevent them from forming in the first place, it’s a huge breakthrough.”

He further explains that “What IGC is going to do with this patent is take it to clinical trials. We have productized it, and there is more than sufficient evidence. So, now we are now talking to several different places to see where we can begin clinical testing on the path to FDA approval.”

“[W]e are the only cannabis-based pharmaceutical company working on Alzheimer’s,” Mukunda concluded.

For more information, please visit the company’s website at www.IGCInc.us

• Origo to acquire High Times in transaction valued at $250 million
• High Times will be traded under Origo’s ticker symbol following close of acquisition
• Better access to capital and an elevated profile will enable High Times to expand its brand and fund new opportunities

Origo Acquisition Corp. (NASDAQ: OACQ) is acquiring the iconic marijuana media company High Times Holding Corp. in a move that allows High Times to become publicly traded, according to a MarketWatch article published July 31 (http://dtn.fm/Me6cL).

Origo will acquire all of High Times’ equity in a transaction valued at $250 million. Origo will give 23.5 million new shares to High Times and end up with 83% of the company. If the acquisition goes through, High Times will be traded under Origo’s ticker symbol, OACQ, on the NASDAQ Capital Market.

High Times Holding Corp. is the publisher of High Times Magazine, which began operations in 1974. High Times announced the move July 27 (http://dtn.fm/rKg5N), calling the acquisition a merger and saying the company has been positioning itself to better capitalize on future growth by broadening its focus on events, licensing and media, the company’s three primary segments.

Better access to capital and an elevated profile will enable High Times to expand its brand and fund new opportunities to leverage nationwide medical and recreational use initiatives, the announcement states. The public market is the best way to capture and fund opportunities and encourage innovations, High Times CEO Adam Levin said in the announcement.

Origo Acquisition Corp. was founded in December 2014 and is headquartered in New York. The company is publicly traded, although it has no existing line of business.

Origo is a special-purpose acquisition vehicle, also known as a shell company or a “blank-check company.” Decades ago, blank-check companies had a bad reputation; they were popular in the 1980s but ran into regulatory issues and became known as fraudulent.

In the 2000s, special purpose acquisition vehicle companies, or SPACs, regained popularity. This year alone, 17 SPACs have gone public, per MarketWatch statistics. The number is on-track to surpass 20 in 2017; in 2016, 13 SPACs went public.

Funds raised in an IPO by a SPAC are placed in a trust account, and the money can only be released in the event of a transaction or acquisition which a majority of the company’s public shareholders approve.

SPACs are required to acquire at least one company within two years of formation. If they don’t, investors get their money back. Because of this, SPACs are considered low-risk and are favored by hedge funds and other large investors.

For more information on High Times, visit the company’s website at www.HighTimes.com/about